Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3701-3707

  Van Wart, S A ^a   Owen, J S ^a,b   Ludwig, E A ^a   Meagher, A K ^a   Korth Bradley, J M ^c   Cirincione, B B ^a  

^a Albany Medical College   (United States)

^b AUBURN UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ABDOMINAL INFECTION; ADULT; AGED; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INFUSION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN INFECTION; STATISTICAL ANALYSIS; STEADY STATE;

ABDOMEN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; MODELS, STATISTICAL; POPULATION; SKIN DISEASES, INFECTIOUS;

EID: 33750603592     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01636-05     Document Type: Article

References (23)

1. Babinchak, T., E. J. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trials data. Clin. Infect. Dis. 41(Suppl. 5):S354-S367.
2. Beal, S. L., and L. B. Sheiner (ed.). 1992. NONMEM users guides. GloboMax, LLC, Hanover, Md.
3. Bradford, P. A. 2004. Tigecycline: a first in class glycylcycline. Clin. Microbiol. Newsl. 26:163-168.
4. Conte, J. E., J. A. Golden, M. G. Kelly, and E. Zurlinden. 2005. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25:523-529.
5. Ellis-Grosse, E. J., T. Babinchak, N. Dartois, G. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5):S341-S353.
6. Gabrielsson, J., and D. Weiner. 2000. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd ed. Swedish Pharmaceutical Press, Stockholm, Sweden.
7. Gales, A. G., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
8. Huxley, J. S. 1932. Problems of relative growth. The Dial Press, New York, N.Y.
9. Jelliffe, R. W. 1973. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79:604-605.
10. Kenny, G. E., and F. D. Cartwright. 2001. Susceptibilities of Mycoplasma hominus, M. pneumoniae, and Ureoplasma urealyticum to GAR-936, dalfopristin, dirthromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinopristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45:2604-2608.
11. Meagher, A. K., P. G. Ambrose, T. H. Grasela, and E. J. Ellis-Grosse. 2005. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41(Suppl. 5):S333-S340.
12. Mordenti, J. Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028-1038.
13. Muralidharan, G., R. J. Fruncillo, M. Micalizzi, D. G. Raible, and S. M. Troy. 2005. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother. 49:1656-1659.
14. Muralidharan, G., M. Micalizzi, J. Speth, D. Raible, and S. Troy. 2005. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49:220-229.
15. Naganathan, V., and P. Smabrook. 2003. Gender-differences in volumetric bone density: a study of opposite-sex twins. Osteoporos. Int. 14:564-569.
16. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
17. Roblin, P. M., and M. R. Hammerschlag. 2000. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents 16:61-63.
18. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
19. Sum, P. E., and P. Petersen. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
20. Sun, H. K., C. T. Ong, A. Umer, D. Harper, S. Troy, C. H. Nightingale, and D. P. Nicolau. 2005. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49:1629-1632.
21. Wallace, R. J., B. A. Brown-Elliott, C. J. Crist, and R. J. Wallace. 2002. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isoloates of nontuberous mycobacteria. Antimicrob. Agents Chemother. 46:3164-3167.
22. Wyeth Pharmaceuticals Inc. 2005. Tygacil® (tigecycline) product information. Wyeth Pharmaceuticals Inc., Philadelphia, PA.
23. Zhanel, G. C., K. Homenuik, K. Nichol, A. Noreddin, L. Vercaigne, J. Embil, A. Gin, J. A. Karlowsky, and D. J. Hoban. 2001. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64:63-88.